# Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib

> **NCT05464173** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Biyun Wang, MD** · enrollment: 44 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Abemaciclib
- **DRUG:** endocrinotherapy（doctor's choice）

## Key facts

- **NCT ID:** NCT05464173
- **Lead sponsor:** Biyun Wang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05464173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05464173, "Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05464173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*